Quest Laboratories Limited — Important, 14-11-2024: Financial Result Updates

**Consolidated Financials**: For the half year ended on September 30, 2024, Quest Laboratories reported total income of ₹4,345.80 crore, reflecting a year-over-year increase attributed to rising demand and market expansion in the pharmaceuticals sector.

**Revenue Growth**: The revenue growth of approximately 8.6% compared to the previous period is driven by increased operational efficiency, an expanding client base, and stronger product offerings.

**Profit and EPS**: The company achieved a net profit of ₹800.84 crore for the half year, up from ₹631.96 crore a year prior. This translates to basic Earnings Per Share (EPS) of ₹4.89, indicating improved profitability supported by effective cost management.

**Operational Costs**: Total operational expenses stood at ₹3,206.11 crore, a decrease of around 11% due to tighter cost control measures. Notably, reductions in material and employee-related expenses contributed positively to this outcome.

**Balance Sheet & Cash Flow Statement**: The balance sheet reflects total assets of ₹11,279.09 crore, indicating solid financial stability. The cash flow statement shows a net cash outflow from operating activities of ₹796.06 crore, mainly driven by increased working capital needs, though the firm maintained significant liquidity with a cash position of ₹11.63 crore.

**Strategic Position and Outlook**: Quest Laboratories appears well-positioned for continued growth, with a focus on operational efficiencies, cost management, and strategic market expansions. Positive market sentiment suggests further upside potential, provided the company manages its cash flows effectively.

**Investor Insight**: Given the strong growth potential and solid financial performance, the stock appears to be a good pick for investors seeking long-term growth opportunities.